CRISPR 2.0: The First Gene-Editing Therapy Approval

The medical world witnessed a watershed moment in late 2023 when regulators in the UK and the US granted approval to Casgevy. This therapy represents the first-ever medical treatment approved that utilizes CRISPR gene-editing technology. For patients suffering from sickle cell disease, this is not just a scientific breakthrough; it is a potential functional cure for a lifetime of debilitating pain.

The Approval of Casgevy

On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved Casgevy (exagamglogene autotemcel) for the treatment of sickle cell disease in patients 12 years and older. This followed a similar authorization by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2023.

Developed through a partnership between Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is designed to treat the underlying cause of the disease rather than just managing symptoms. The approval centers on patients who suffer from recurrent vaso-occlusive crises (VOCs), which are severe pain episodes caused by sickle-shaped red blood cells blocking blood flow.

During the clinical trials that led to this approval, the results were staggering. Out of 31 patients evaluated for efficacy, 29 remained free of severe pain crises for at least 12 months after treatment. This high success rate provided the confidence regulators needed to greenlight the therapy.

How the Technology Works

To understand why this is called “CRISPR 2.0,” one must look at the mechanism. The original discovery of CRISPR was a tool for research. Casgevy is the practical application of that tool in human medicine.

Sickle cell disease is caused by a mutation in hemoglobin, the protein in red blood cells that carries oxygen. Casgevy does not fix this mutation directly. Instead, it uses a clever workaround involving fetal hemoglobin.

  1. Fetal Hemoglobin (HbF): Babies are born with a form of hemoglobin that naturally resists sickling. However, shortly after birth, the body activates a “genetic switch” called BCL11A to stop producing fetal hemoglobin and start producing adult hemoglobin.
  2. The Edit: Casgevy uses CRISPR/Cas9 molecular scissors to enter the patient’s stem cells and cut the DNA at the BCL11A gene.
  3. The Result: By disabling this switch, the body resumes the production of fetal hemoglobin. This healthy hemoglobin dilutes the defective sickle cells, preventing them from clumping together and causing pain.

The Patient Journey and Treatment Process

While the science is elegant, the patient experience is physically demanding. Casgevy is not a simple pill or injection. It involves a multi-month procedure that requires hospitalization.

  • Collection: Doctors first collect stem cells from the patient’s blood through a process called apheresis.
  • Manufacturing: These cells are shipped to a manufacturing laboratory. There, technicians use CRISPR to edit the DNA of the cells. This process can take up to six months.
  • Conditioning: Before the edited cells can be returned, the patient must undergo high-dose chemotherapy using a drug called busulfan. This clears out the bone marrow to make room for the new cells. This phase is risky and difficult, often requiring a hospital stay of several weeks.
  • Infusion: The edited stem cells are infused back into the patient. Over time, they engraft and begin producing healthy red blood cells containing fetal hemoglobin.

The Cost of a Cure

The approval of Casgevy brought immediate attention to the economics of genetic medicine. Vertex Pharmaceuticals set the U.S. list price for Casgevy at $2.2 million for a one-time treatment.

While this number appears astronomical, health economists weigh it against the lifetime cost of managing severe sickle cell disease. The Institute for Clinical and Economic Review (ICER) suggests that the lifetime health costs for a patient with severe sickle cell can range between $4 million and $6 million due to frequent hospitalizations and transfusions.

Alongside Casgevy, the FDA also approved a competitor therapy named Lyfgenia by Bluebird Bio on the same day. Lyfgenia uses a different method (a lentiviral vector) to add a healthy gene rather than editing an existing one. Bluebird Bio set the price for Lyfgenia at $3.1 million, making Casgevy the more affordable option of the two gene therapies.

Safety and Long-Term Considerations

The FDA approval came with close scrutiny regarding safety. The primary concern with CRISPR technology is “off-target effects,” where the molecular scissors might cut the wrong piece of DNA. Vertex and CRISPR Therapeutics conducted extensive analysis to show that such errors were not occurring in their therapeutic samples.

However, the treatment does carry risks associated with the procedure itself:

  • Chemotherapy Side Effects: The busulfan conditioning causes hair loss, nausea, and a compromised immune system, leaving patients vulnerable to infection during recovery.
  • Fertility: The chemotherapy required to prepare the bone marrow can cause infertility. Patients are often advised to preserve sperm or eggs before undergoing the procedure.
  • Long-Term Monitoring: Because this is a permanent change to the patient’s DNA, the FDA requires a 15-year follow-up study for all patients receiving the therapy to monitor for any long-term malignancies or adverse effects.

Beyond Sickle Cell: Beta Thalassemia

The success of Casgevy extends beyond sickle cell disease. In January 2024, the FDA expanded the approval of Casgevy to treat transfusion-dependent beta-thalassemia (TDT). Like sickle cell, TDT is a blood disorder affecting hemoglobin.

Patients with TDT typically require blood transfusions every few weeks to survive. In clinical trials, 93% of patients treated with Casgevy remained transfusion-free for at least a year. This dual approval solidifies the platform’s viability and suggests that gene editing will soon address other genetic conditions affecting the blood, liver, and muscles.

Frequently Asked Questions

Is Casgevy a permanent cure? Doctors refer to it as a “functional cure.” While the patient still carries the genetic mutation for sickle cell, the treatment allows their body to produce enough healthy fetal hemoglobin to prevent symptoms. The edited stem cells are expected to persist for the patient’s lifetime.

Who is eligible for this treatment? Currently, the FDA has approved Casgevy for patients aged 12 and older who have recurrent vaso-occlusive crises. It is not yet approved for younger children, though trials for younger age groups are underway.

Does insurance cover the $2.2 million cost? Most major commercial insurers and Medicaid programs are developing coverage plans for gene therapies. Because the treatment replaces expensive lifetime care, payers are generally incentivized to cover it, though they may require strict prior authorization to ensure the patient meets specific medical severity criteria.

Can the treatment be reversed? No. Gene editing makes a permanent change to the DNA in the stem cells. Once those cells are infused and engraft in the bone marrow, the change is permanent.

Where is the treatment available? Casgevy is only available at authorized treatment centers (ATCs) that have experience with stem cell transplants and gene therapy. Vertex is establishing a network of roughly 50 to 75 hospitals across the United States to administer the therapy.